Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
NCT05796401 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2026-04-20
Summary
Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset. Early intervention programs improve the general outcome with staged care strategies, supporting the view that the period before and around the first episode of psychosis is a window of opportunity for improving its functional recovery.
Pioneering epigenetic analyses indicate that psychosis onset involves oxidative stress and inflammation suggesting that neuroprotective strategies could limit or even prevent the onset of or the transition into a chronic disorder. Several biological factors associated with the emergence of psychosis can all be rectified by using safe and easily accepted supplements including alterations folate deficiency/hyperhomocysteinemia; redox imbalance and deficit in polyunsaturated fatty acids (PUFA). The prevalence of these anomalies (20-30%) justifies a systematic detection and could guide personalised add-on strategy.
Cognitive remediation improves quality of life (QoL) and functional outcome in patients with chronic psychosis. It would even be more efficacious in the early phase of psychosis by tackling the negative impact of psychosis on education achievement and employment. However, cognitive dysfunctions are often overlooked in patients at ultra-high risk (UHR) for psychosis and patient with a first episode of psychosis (FEP) and cognitive remediation is not always accessible. New technologies can provide us with youth-friendly, non-stigmatising tools, such as applications with cognitive strategies, motivational tools and functioning guidance personalised according to the need of each individual. Patients can have access to it, wherever they live.
Early psychosis can be associated with inflammation, metabolic deficiency, as well as early structural brain anomalies that reflect brain plasticity abilities and could influence the prognosis and response to cognitive training.
The study hypothesis is that promoting neuroplasticity by cognitive training and personalised virtual psychoeducation guidance could attenuate or reverse early cognitive deficits and improve the overall functional outcome in young patients UHR or FEP and that this effect is modulated by individual brain plasticity abilities. The overall objective of PsyCARE\_trial is to improve early intervention in psychosis by providing a composite personalised care (CPC) that will enable personalised cognitive training and psychoeducation guidance, adapted to individuals' needs, cognitive abilities and biological background.
Conditions
Interventions
- BEHAVIORAL
-
Cognitive training
Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks +/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))
- DRUG
-
Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC
Personalised neuroprotective medication adapted to the individual's biological profile : * Vitamin B12 : 500 micrograms per day * Folinic acid : 50 mg per day * Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day * N-acetyl-cysteine (NAC) : 2400 mg per day duration of supplementation(s) : 12 weeks
- OTHER
-
Treatment as usual (TAU)
Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I\_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
Sponsors & Collaborators
-
Centre Hospitalier St Anne
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 15 Years
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-15
- Primary Completion
- 2026-12-15
- Completion
- 2029-02-15
Countries
- France
Study Locations
More Related Trials
-
Early and Short Psycho-educational Lifestyle Intervention
NCT02657941 ·Status: TERMINATED ·Phase: NA
-
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
NCT04874974 ·Status: COMPLETED ·Phase: NA
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA
-
Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms
NCT06314204 ·Status: RECRUITING
-
Enhancing the Prospective Prediction of Psychosis
NCT00291200 ·Status: COMPLETED
-
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
NCT01714661 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
NCT02874560 ·Status: COMPLETED
-
Group Psychoeducation to Promote Independent Living in Individuals With Psychiatric Disorders
NCT07317388 ·Status: RECRUITING
-
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
NCT00204061 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
NCT02566057 ·Status: COMPLETED ·Phase: NA
-
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCT00419146 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
NCT05813457 ·Status: RECRUITING ·Phase: NA
-
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
NCT01936220 ·Status: UNKNOWN ·Phase: NA
-
Psychological Intervention for Persons in the Early Initial Prodromal State
NCT00204087 ·Status: UNKNOWN ·Phase: PHASE3
-
Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age
NCT04280367 ·Status: COMPLETED
-
Cognitive Phenotyping of Severe Psychiatric Disorders (PSYCOG)
NCT05025566 ·Status: NOT_YET_RECRUITING
-
Uppsala Psychosis Cohort
NCT05763966 ·Status: RECRUITING
-
Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis
NCT06542640 ·Status: RECRUITING ·Phase: NA
-
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
NCT04005378 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
NCT06870305 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia
NCT05839613 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
NCT04370730 ·Status: RECRUITING ·Phase: NA
-
Effect of Experience Sharing and Mutual Assistance on Insight and Recovery During the First Psychotic Episode
NCT06263933 ·Status: RECRUITING ·Phase: NA
-
Study of the Impact on the Therapeutic Alliance of a Short Initial Psychoeducation Programme in Patients With Early Schizophrenia
NCT04867681 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA